Health care partner Mark Barnes (Boston) and life sciences partner Gregory Levine (Washington, D.C.) authored a Nov. 15 article published in Bloomberg BNA’s Medical Research Law & Policy Report, that examines the implementation and consequences of new U.S. Food and Drug Administration (FDA) policies that streamline and reduce administrative delays in the process of applying for expanded access use of investigational drugs, medical devices and biological products.
Expanded access programs allow investigational medical products to be made available outside clinical trials to patients suffering from serious diseases for whom no satisfactory alternative treatment options exist.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.